Skip to content
    ILMN
    Earnings call· Mar 2026(Q1 FY26)

    ILLUMINA Q1 FY26 earnings call ILMN

    Apr 30, 2026 Source

    Executive summary

    Illumina Q1 FY26 — Strong Clinical Growth and NovaSeq X Demand Drive Raised Outlook

    Illumina delivered a strong Q1 FY26, exceeding revenue, margin, and EPS guidance, driven by robust clinical market momentum and higher-than-expected NovaSeq X placements. The company raised its full-year outlook, reflecting confidence in its strategy and continued innovation on the NovaSeq X platform, despite ongoing caution in research markets and near-term inflationary pressures.

    Highlights

    5

    • Q1 revenue of $1.09 billion, up 4.8% year-over-year, came in $20 million above the midpoint of guidance.

    • Non-GAAP diluted EPS of $1.15 per share grew 19% year-over-year, approximately $0.10 above guidance midpoint.

    • Rest of World organic growth was 3.5%, above the high end of guidance, driven by sequencing consumables and instruments.

    • Clinical sequencing consumable demand grew 20% ex China for the second consecutive quarter.

    • Over 80 NovaSeq X placements in the quarter, approximately 20 more than Q1 2025, with strong demand in clinical markets.

    Concerns

    3

    • Sequencing consumables in research and applied declined 12% ex China, reflecting continued funding uncertainty.

    • Microarrays business was down 20% on a Rest of World organic basis, largely due to specific large direct-to-consumer customers.

    • Q2 operating margins are expected to be approximately 22%, reflecting a higher mix of instrument revenue, inflationary pressures from freight and electronic components, and a full quarter of SomaLogic.

    Guidance & targets

    19
    CategoryTargetConfidence
    Full-year 2026 Reported Revenue
    $4.52 billion to $4.62 billion
    high materiality
    High
    Full-year 2026 Acquired Revenue Contribution
    1.5 to 2 points of growth
    medium materiality
    High
    Full-year 2026 Currency Impact
    approximately 1% of growth
    medium materiality
    High
    Full-year 2026 Rest of World Organic Growth
    2% to 4%
    high materiality
    High
    Full-year 2026 Rest of World Organic Sequencing Consumables Growth
    low to mid-single-digit growth
    medium materiality
    High
    Full-year 2026 Clinical Consumables Growth
    double digit to mid-teens
    medium materiality
    High
    Full-year 2026 Research and Applied Consumables Growth
    declining mid- to high single digits
    medium materiality
    High
    Full-year 2026 Instrument Growth
    flat to low single-digit growth year-over-year
    medium materiality
    High
    Full-year 2026 Operating Margins
    23.4% to 23.6%
    high materiality
    High
    Full-year 2026 Non-GAAP Diluted EPS
    $5.15 to $5.30
    high materiality
    High
    Full-year 2026 EPS Growth (excluding SomaLogic)
    12% at the midpoint
    medium materiality
    High
    Q2 2026 Rest of World Organic Revenue Growth
    4% to 6%
    medium materiality
    High
    Q2 2026 Reported Revenue
    $1.12 billion to $1.14 billion
    medium materiality
    High
    Q2 2026 Non-GAAP EPS
    $1.20 to $1.25
    medium materiality
    High
    Q2 2026 Operating Margins
    approximately 22%
    medium materiality
    High
    2027 Revenue Growth Target
    high single-digit revenue growth
    high materiality
    High
    2027 Margin Expansion Target
    continued margin expansion
    high materiality
    High
    2027 EPS Growth Target
    double-digit to teens EPS growth
    high materiality
    High
    2026 Margin Expansion (excluding acquisitions)
    approximately 350 basis points
    medium materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Sequencing Consumables
    High throughput volume drove most of the revenue growth as the NovaSeq X installed base continues to expand and utilization increased year-over-year. Clinical demand continues to expand, driven by new trials and information-rich sequencing-intensive tests. Research and applied declined due to funding uncertainty.
    Rest of World organic growth: 5%Clinical sequencing consumable demand growth ex China: 20%Research and applied sequencing consumables decline ex China: 12%Volumes transitioned to NovaSeq X: 82%Revenue transitioned to NovaSeq X: 55%Research and applied volume on NovaSeq X: 90%Clinical volume on NovaSeq X: 76%
    		$726M4%——
    Sequencing Instruments
    Driven by increased sales of NovaSeq X, with strong demand especially in clinical markets, including several multiunit orders. The company was supply constrained on NovaSeq X units in Q1.
    Rest of World organic growth: 10%NovaSeq X placements: >80 units
    		$118M9%——
    Sequencing Service and Other
    The timing of strategic partnerships and data deals can be lumpy in this segment as BioInsight scales up.
    Rest of World organic growth: 5%
    		$151M7%——
    Microarrays
    Largely due to specific large customers in the direct-to-consumer segment.
    Rest of World organic decline: 20%
    		————

    Operational metrics

    18
    Non-GAAP Gross Margin
    68.2%up 80 basis points year-over-year
    Q1 FY26

    Driven by cost efficiencies and higher revenue, partly offset by tariffs.

    Non-GAAP Operating Expenses
    $506Mup 3% year-over-year
    Q1 FY26

    Largely reflects the addition of the SomaLogic team.

    Non-GAAP Operating Margin
    21.9%expanding approximately 150 basis points year-over-year
    Q1 FY26

    Reflecting increased operating leverage from an improved cost structure.

    Non-GAAP Other Expense
    $15M
    Q1 FY26

    Largely comprised of net interest expense.

    Non-GAAP Tax Rate
    20.5%
    Q1 FY26
    Non-GAAP EPS
    $1.15grew approximately 19% year-over-year
    Q1 FY26

    Came in about $0.10 above the midpoint of guidance.

    Average Diluted Shares
    154Mdown $5M year-over-year
    Q1 FY26

    Reflecting share repurchases throughout the year.

    Cash Flow Provided by Operations
    $289M
    Q1 FY26
    Capital Expenditures
    $38M
    Q1 FY26
    Share Repurchases
    $242M
    Q1 FY26
    Remaining Share Repurchase Authorization
    $400M
    Q1 FY26

    From current authorization.

    New Share Repurchase Authorization
    $1.5B
    announced Q1 FY26

    Authorized by Illumina's Board of Directors.

    Cash, Cash Equivalents and Short-Term Investments
    $1.16B
    Q1 FY26

    At quarter end.

    Gross Leverage
    1.5x
    Q1 FY26
    SomaLogic Acquisition Net Cash Payment
    $363M
    Q1 FY26

    Plus potential royalties and milestone payments.

    SomaLogic First Milestone Payment
    $25M
    post Q1 FY26

    Paid subsequent to quarter end for achievement of certain 2025 targets.

    Total Sequencing GD Output Growth
    >30%year-over-year
    Q1 FY26

    Clinical growth well above this.

    NovaSeq X Pull-Through
    >$1.3M
    annualized

    Expected to continue at this level or above.

    Industry KPIs

    7
    MetricValueDetails
    Revenue EPS guidance$4.52B-$4.62BUSD
    Pricing price realization—
    M a contribution synergies—
    Segment organic revenue growth—
    End market demand funnel commentary—
    Instruments vs consumables services mix82%%
    Organic core revenue growth by end market3.5%%

    Product announcements

    5
    ProductTypeDetails
    TruPathlaunch
    Spatial Transcriptomics Offeringlaunch
    NovaSeq X 18-month Roadmaproadmap
    BioInsightupdate
    Billion Cell Atlasmilestone

    Deals & partnerships

    1
    SomaLogicacquisition$363M net cash payment plus potential royalties and milestone payments

    Acquisition closed on January 30. First milestone payment for achievement of certain 2025 targets.

    Risks & headwinds

    4
    Research and academic market funding uncertaintyQ1 FY26, expected to continue through FY26

    Sequencing consumables in research and applied declined 12% ex China.

    Mitigation: Investing in leading technologies (proteomics, single cell, spatial) to drive long-term adoption. Expect return to growth when funding uncertainties ease.

    Microarrays business declineQ1 FY26

    Down 20% on a Rest of World organic basis.

    Mitigation: Attributed to specific large direct-to-consumer segment customers, implying a specific customer issue rather than broad market decline.

    Inflationary pressuresQ2 FY26 and near-term

    Impact on Q2 operating margins, specifically freight costs and higher cost of electronic components.

    Mitigation: Taking several mitigating actions to fully offset the impact during the year, reflected in implied margin improvement for the rest of the year.

    NovaSeq X supply constraintsQ1 FY26, continuing into Q2 and Q3

    Supply constrained on the number of NovaSeq X units that were placed in Q1.

    Mitigation: Investing to scale the supply of NovaSeq X units, with progress expected through Q2 and into Q3.

    Q&A highlights

    7

    Given the strong Q1 beat and positive trends in instruments and clinical, why wasn't the full-year organic revenue guidance raised more significantly?

    Management stated that raising guidance after only one quarter, even by $20 million (0.5 point), demonstrates confidence and positions them towards the higher end of the previously stated range. They indicated no additional cautiousness beyond what was already factored into the initial guidance.

    “we are leaning in by raising both the top line and the bottom line early -- very early in the quarter. So I think we're signaling all the right things here.”

    asked by Vijay Kumar · answered by Jacob Thaysen

    2 min read5 chapters

    Detailed Narrative

    01

    Q1 Performance Exceeds Expectations

    Illumina reported a strong start to 2026, with Q1 revenue of $1.09 billion, non-GAAP gross margin of 68.2%, and non-GAAP diluted EPS of $1.15, all surpassing guidance. This outperformance was attributed to disciplined execution and strength in clinical markets, leading to a raised full-year outlook for revenue, operating margin, and EPS. The company's Rest of World organic growth reached 3.5%, exceeding the high end of its guidance.

    02

    Clinical Market Momentum and NovaSeq X Adoption

    The clinical segment continues to be a significant growth driver, comprising over 65% of sequencing consumables revenue and growing 20% ex China for the second consecutive quarter. This growth is fueled by the expansion of sequencing-based diagnostics and increased use of data-intensive applications like comprehensive genomic profiling and whole genome sequencing. NovaSeq X placements were robust, with over 80 units placed in Q1, approximately 20 more than Q1 2025, indicating strong demand, particularly in clinical settings.

    03

    Innovation and Product Roadmap

    Illumina highlighted its innovation strategy, including the launch of TruPath for simplified whole genome sequencing in rare diseases, reducing hands-on time to about 10 minutes. The company also showcased its spatial transcriptomics offering, on track for launch later this year, which has shown promise in challenging sample types. Furthermore, an 18-month roadmap for NovaSeq X was introduced, featuring new 14B and 35B flow cells, staggered runs, and Q70 performance improvements to enhance flexibility, throughput, and workflow efficiency.

    04

    Cautious Research Market and Future Outlook

    While clinical markets thrive, demand in research and academic markets remains cautious due to funding uncertainty, with consumables declining 12% ex China. However, management noted potential upside from improving NIH funding. The company remains confident in its long-term strategy, aiming for high single-digit revenue growth, continued margin expansion, and double-digit to teens EPS growth by 2027, supported by ongoing R&D investments.

    05

    Capital Allocation and SomaLogic Integration

    Illumina generated $251 million in free cash flow in Q1 and repurchased 2 million shares for $242 million. The Board authorized an additional $1.5 billion in share repurchases, bringing total authorization to $1.9 billion. The acquisition of SomaLogic closed on January 30, performing in line with expectations, and the company paid a $25 million milestone post-quarter end. Gross leverage stood at approximately 1.5x gross debt to LTM EBITDA.

    AI-generated summary of the company’s earnings call. Not investment advice.